Lockwood acquires medical animation studio ‘Random42’ from Graphite Capital
The partnership between Lockwood and Random42 expands the capabilities and geographic footprint for both organizations.
The partnership between Lockwood and Random42 expands the capabilities and geographic footprint for both organizations.
Facility features LED lighting, solar panels, automation and innovative temperature-controlled systems to maximize efficiency and minimize environmental impact
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
120+ members of multi-disciplinary medical team are trained to provide seamless, outcome driven trauma and emergency care
By 2025, Cipla plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry.
Companies concluded memorandum of understanding that Takeda will continue to provide distribution support for the Moderna COVID-19 vaccines for a transitional period
This agreement is in addition to the $92 million filling line expansion announced in November 2021
Subscribe To Our Newsletter & Stay Updated